ODT’s Most-Read Stories This Week—Dec. 16

Orthofix ascended to pageview king this past week on the ODT website.

The placement is hardly surprising considering the Lewisville, Texas-based company achieved the ranking based on another personnel announcement. Orthofix appointed three new independent directors to its board following a cooperating agreement made with Engine Capital, which owns about 8.2% of the company’s outstanding shares. The announcement was made just two weeks after Orthofix named its new CEO (Massimo Calafiore, as of Jan. 1). The three new independent directors are: Alan Bazaar, CEO of wealth management firm Hollow Brook Wealth Management; Michael Finegan, CEO of Acera Surgical and former Orthofix chief strategy officer; and Charles Kummeth, president/CEO of Bio-Techne.

Runner-up to Orthofix’s personnel plug was word of ZimVie Inc.’s FDA clearance of its Vital Spinal Fixation System, including instruments for use with Brainlab Spine & Trauma Navigation. The clearance follows execution of the companies’ Development Cooperation Agreement, announced in March 2023, to achieve compatibility between ZimVie’s Vital and Virage systems and Brainlab Spine & Trauma Navigation, which helps surgeons plan and execute spinal procedures, accurately place pedicle screws, and minimize radiation exposure.

NeuroMetrix drove traffic with promising study data for long COVID neurostimulation treatment, and OssDsign followed suit with a change in its business strategy. Finally, RevBio made cyberwaves for winning a $3.4 million NIH grant to further develop its TETRANITE technology.   

1. Orthofix Welcomes 3 New Independent Directors to Board

2. ZimVie’s Vital Spinal Fixation System Compatible With Brainlab Spine & Trauma Navigation

3. NeuroMetrix Pilot Trial Data Shows Neurostimulation Could Quell Long COVID Pain

4. OssDsign Realigning its Strategy to Focus on Orthobiologics

5. NIH Awards RevBio $3.4M Grant to Develop its Regenerative Bone Adhesive